Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anything can happen. It is completely shorted
Look for the trend and watch out for sudden changes
Look ESI, IS GOOD!
Rosetta Stone confirms buyout interest $9/$10 x share.
May 29 2015, 09:39 ET Seeking Alpha
Following a Thursday afternoon Mergermarket report stating the company has received a buyout offer in the $9-$10/share range, Rosetta Stone (NYSE:RST) says its board "has received an expression of interest from RDG Capital Fund Management," and that it will "carefully evaluate" the proposal.
Rosetta, which traded above $10 as recently as early March, reiterates it's "actively implementing its strategic plan, which it believes will deliver attractive value for shareholders."
http://seekingalpha.com/news/2551296-rosetta-stone-confirms-buyout-interest-shares-plus-11_5-percent
At any time, RST is purchased!!!Activist RDG Looking to Solve Rosetta Stone -- Market Talk
10:07 am ET May 29, 2015 (Dow Jones)
10:07 EDT - Russell Glass, a former member of Carl Icahn's team, has apparently approached language-learning company Rosetta Stone (RST) about a potential deal, RST discloses. His RDG Capital typically pushes holdings to sell, and often makes an offer to buy, so the move is typical for this activist. RST doesn't put a price on the "expression of interest" it says it will evaluate. But the company also reiterates it believes its own plans are good for shareholders. The stock has been beaten down recently, having fallen 34% this year through Thursday before today amid a reorganization and strategy change. After that was unveiled, the CEO left two weeks later. RST is up 17% at $7.53, cutting the month's swoon to 10%. (david.benoit@wsj.com; @DaveCBenoit)
(END) Dow Jones Newswires
May 29, 2015 10:07 ET (14:07 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Rosetta Stone (RST) Announces Receipt of Interest from RDG Capital Fund Management; Will Evaluate ($10/12 X Share?)
http://www.streetinsider.com/Corporate+News/Rosetta+Stone+%28RST%29+Announces+Receipt+of+Interest+from+RDG+Capital+Fund+Management%3B+Will+Evaluate/10607138.html?si_email_click=2015052909
(RST) Announces Receipt of Interest from RDG Capital Fund Management; Will Evaluate(OPPORTUNITY)
May 29, 2015 9:29 AM EDT
Rosetta Stone (NYSE: RST) announced that its Board of Directors has received an expression of interest from RDG Capital Fund Management. The Board stated that it will carefully evaluate the expression of interest. The Board also said that the Company is actively implementing its strategic plan, which it believes will deliver attractive value for shareholders.
http://www.streetinsider.com/Corporate+News/Rosetta+Stone+%28RST%29+Announces+Receipt+of+Interest+from+RDG+Capital+Fund+Management%3B+Will+Evaluate/10607138.html?si_email_click=2015052909
Look, TBIO, Pre market $2.72+ 44% PBMD $2.81+14%
Good news
A sell signal for these stocks: Oncothyreon Inc (USA) (NASDAQ:ONTY), Avago Technologies Ltd (NASDAQ:AVGO), Delcath Systems, Inc. (NASDAQ:DCTH)
Developed J. Welles Wilder, the Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI is an extremely popular momentum indicator that has been featured in a number of articles, interviews and books over the years. In particular, Constance Brown’s book, Technical Analysis for the Trading Professional, features the concept of bull market and bear market ranges for RSI. Andrew Cardwell, Brown’s RSI mentor, introduced positive and negative reversals for RSI. In addition, Cardwell turned the notion of divergence, literally and figuratively, on its head.
RSI oscillates between zero and 100. Traditionally, and according to Wilder, RSI is considered overbought when above 70 and oversold when below 30. Signals can also be generated by looking for divergences, failure swings and centerline crossovers. RSI can also be used to identify the general trend.
Oncothyreon Inc (USA) (NASDAQ:ONTY) is now in overbought territory with an RSI value of 77.56. The stock is up +106.13% in one month through last close, to $3.36, showing a +108.70% return during the past three months. The share price is up from fifty two week low with +138.30% and low from fifty two week high with -6.67%. It stands +86.65% above the average-price of 50 days and +72.22% compared with the SMA 20.
Avago Technologies Ltd (NASDAQ:AVGO) has a RSI reading of 74.14, with a 1-year total return of +102.35% and a six-month return of +57.88%. The stock is up +17.76% in one month through last close, to $141.49, showing a +25.94% return during the past three months. The share price is up from fifty two week low with +108.03% and up from fifty two week high with +3.82%. It stands +12.65% above the average-price of 50 days and +14.07% compared with the SMA 20.
Delcath Systems, Inc. (NASDAQ:DCTH) currently has an RSI of 79.90. The stock is up +39.22% in one month through last close, to $1.42, showing a +19.33% return during the past three months. The share price is up from fifty two week low with +77.50% and low from fifty two week high with -52.67%. It stands +48.26% above the average-price of 50 days and +62.94% compared with the SMA 20.
http://www.wsobserver.com/a-sell-signal-for-these-stocks-oncothyreon-inc-usa-nasdaqonty-avago-technologies-ltd-nasdaqavgo-delcath-systems-inc-nasdaqdcth/7216402/
The main Chart in shorted.This chart is very important for an investor.
http://stockcharts.com/freecharts/gallery.html?s=ONTY
Comparative analysis: SHORTED TOTAL.
ONTY VS S&P 500 INDEX + 125%
ONTY VS USA/HEALTH CARE +125%
ONTY VS USA/BIOTECHNOLOGY +125%
-------------------------
SLTD:Markit short selling activity:Low, Be careful
ONTY: Big short sell,101,875 $3.44 11:14 hs +98,773 shares in short $3.42 11:15
Any time, again in fallen!
OHGI is cool
AMERICAN BULLS:STAY LONG,LAST PATTERN:BEARISH HARAMI
Signal Update
Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 05/14/2015, 13 days ago, when the stock price was 1,7530. Since then ONTY has risen by +91,67%.
Market Outlook
Candlesticks warned us today to be on alert with a new bearish pattern. Market attention is now on the downside.more...
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ONTY
Pay close attention to CERE
Ceres Sprouts Off Patent Awarded For Soybean Seed Enhancement
2:53 pm ET May 27, 2015 (Benzinga)
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.
Ceres Inc (NASDAQ: CERE) shares are trading higher by $1.46 at $3.14 in Wednesday's session. The catalyst for the doubling of the agricultural biotechnology company is U.S. patent awarded for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation.
The low-priced volatile issue spiked to the $4 level for the fifth time since March 4, but has not been able to sustain that level for more than one session. That is the case in Wednesday's session as Ceres spike from its low for the day ($1.77) to $4 on the heels of the announcement before retreating to its current level.
It should be noted that other spikes in the issue took place on average volume.
However, the current rally is taking place on much higher than average volume, as 12.3M shares have changed hands compared with its 20-day average of 1M shares with two hours remaining in the session.
ONTY:Markit short selling activity, It is increasing from low to médium.
ONTY must come down to find your balance in the chart. RSI(14)82.28
May be,Turning point in fall $5.38
http://stockcharts.com/h-sc/ui?s=KTOS&p=D&b=5&g=0&id=p26099102557&a=264845671
$3.60 +3.15% Short sellers, attack again RSI(14)83.10 Overbought
Turning point in fall $1.93/2.00
http://stockcharts.com/h-sc/ui?s=ONTY&p=D&b=5&g=0&id=p26099102557&a=264845671
This is bad news, no mistake, The capital reduction. So the problems begin.
One thing is cutting jobs and another to shrink the size of the laboratory.
That's right, may be chapter eleven, any time
Surprise Resurrection Sees Aveo And Prima Pining For The Fjords (IS NOT GOOD)
May 23, 2015 10:54 AM ETAbout: AVEO Pharmaceuticals, Inc. (AVEO), PBMD
When it comes to dead parrots making comebacks it could not have got much more extreme than the severely depressed Aveo Oncology (NASDAQ:AVEO) and Prima Biomed (NASDAQ:PBMD), whose apparently deceased oncology projects suddenly sprung into life this week.
Had they ceased to be or were they just resting? Investors should remain on their guard, especially as closer reading of the disclosures reveals that very little has changed with tivozanib and CVac. Attempts to resurrect these two assets look like little more than a use of pre-Asco biotech fever to raise much-needed cash.
Aveo's tivozanib had been consigned to the scrapheap in renal cell cancer after its Tivo-1 study showed that control-arm patients actually lived longer than those on active treatment, though the primary progression-free survival endpoint was met. A scathing advisory panel was followed by Astellas canning a Europe licensing deal (Adcom double play erases Aveo and Delcath, May 3, 2013).
Prima's CVac - an autologous dendritic cell vaccine bearing a striking similarity to the monumental flop that was Dendreon's (OTCPK:DNDNQ) Provenge - last year flunked an open-label study in 63 epithelial ovarian cancer patients who were in complete remission after first or second-line treatment. CVac missed the primary endpoint of increasing median PFS versus placebo.
At the time, Prima touted a subgroup analysis dredging up a purported positive PFS and overall survival effect in a subgroup of 20 patients who were in second remission, blaming the lack of effect in first remitters on the heterogeneity of this population.
But it then bought the French immuno-oncology group Immutep for $28m and refocused on Immutep's lead asset, IMP321, a MAb against the promising novel inhibitory checkpoint Lag-3. And it threw in the towel with CVac, citing manufacturing complexity and a dwindling patient pool.
Back from the dead
Yet on Tuesday CVac seemed to rise from the dead, with Prima revealing that median overall survival - still in the secondary-remitter subgroup - had still not been reached for CVac after 42 months, versus mOS of 25.5 months for placebo. It was not until yesterday that Prima's stock surged - up 167% over Wednesday's close.
The odd thing is that Prima already had basically the same data a year ago at Asco; the only difference is that at that point mOS for CVac had not been reached after 30 months.
For its part, Aveo rose over 100% yesterday before closing up 39%. This followed the group's highlighting of an Asco abstract of a Tivo-1 extension cohort in which the focus was on patients who had progressed after Nexavar and subsequently got tivozanib; these lived for another 21.6 months on average.
Again, there is very little new about this. The extension part did nothing to wipe out the Tivo-1 flop in first-line use, caused by a poor study design whereby geography meant that tivozanib recipients had few follow-up options while most first-line Nexavar failures actually got tivozanib.
Indeed, the Asco abstract reiterated the 18% higher risk of death on tivozanib versus Nexavarin Tivo-1. A likely reason for the sudden surge in investor interest was Aveo's highlighting of an FDA agreement over a Phase III trial design in third-line use.
Still, all this means is that Aveo will have to fund yet another prospective study - to show tivozanib's benefit in a late setting in a highly competitive cancer. Both it and Prima - if the latter is about to resurrect CVac - will surely need to secure partners or some other kind of funding.
Aveo rose another 20% in early trade, while Prima - sitting on a 600% three-day increase on Thursday - slumped by 43% Friday. Investors will certainly try playing the wave of optimism, though given pre- and post-Asco volatility this is not an area for the faint of heart.
Project Company Study Trial ID
Tivozanib Aveo Oncology Tivo-1, 1st-line renal cancer vs Nexavar NCT01030783
Tivozanib Aveo Oncology Study '902; open-label extension to Tivo-1 NCT01076010
CVac Prima Biomed Can-003, prevention of ovarian cancer relapse NCT01068509
http://seekingalpha.com/article/3207336-surprise-resurrection-sees-aveo-and-prima-pining-for-the-fjords?app=1&auth_param=8qr2:1am155h:8aacf0d8148d097826705a3f286445cb&uprof=44
AMERICAN BULLS:STAY LONG, LAST PATTERN,BEARISH THREE GAP UPS
Signal Update
Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 05/19/2015, 3 days ago, when the stock price was 1,2599. Since then AVEO has risen by +83,35%.
Market Outlook
The market is uncertain with a negative tilt. The traders seem to be in disagreement. The negative sentiment, however, is increasing as evident from the last bearish pattern. So, it is better to be on alert.
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=AVEO
412,1235 SHARES, SHORT,OPEN:$2.30, H:$2.31 L:$2.28, CLOSE:$2.30
15:59:59HS + 34,469 SHARES, YELLOW,$2.31, MARKET CLOSE.
HAPPY HOLIDAY!
AVEO,It is being attacked by short sellers in large quantities of shares!!
The main chart RSI(14)73.48 remains in overbought!, Is very bad.
AVEO preparing for the big fall..Short sell to kill
Almost hit the spot my $2. Monday is a holiday. End, morning killing
Black Friday?$1.20/1.50
http://stockcharts.com/h-sc/ui?s=AVEO&p=D&b=5&g=0&id=p26099102557&a=264845671
BIG SHORTED,2,4 MILLON SHARES, 14:01.It is very difficult to recover. It is a very big shorted
I think I see closer to $ 2 Volume:64 M
The main chart,Turning point in fall $1.17
http://stockcharts.com/h-sc/ui?s=AVEO&p=D&b=5&g=0&id=p26099102557&a=264845671
Short sell and sell off, In fall!
What's Up With The Delayed Reaction In Aveo Pharmaceuticals?
12:01 pm ET May 21, 2015 (Benzinga) Print
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares were trading higher by $1.36 (80 percent) at $2.96 in Thursday's session. The catalyst for the issue doubling in price is favorable results of its TIVO-1 extension study for the treatment of advanced renal cell carcinoma (RCC).
Strangely, that news hit the wires on Wednesday at 7:00 a.m. ET and only instigated a modest rally in the issue from $1.34 to $1.60. The Street's attention led to the substantial boost in volume as it traded 4.37 million shares compared with its day average of 200-day average of 984,000.
On Thursday, The rise on huge volume may have appeared on scanners across the globe, as well as catching the eye of momentum traders. As a result, after a higher open ($1.84 versus Wednesday's close of $1.60), and a measly $0.03 retreat, it exploded to $3.50. Since reaching that elevated level it has retreated under $3.
The issue is now trading in a vacuum area that was created in May 2013, when it cascaded from $7.54 to $2.52 in one week when a class action lawsuit was filed against the company for alleged violations federal securities laws.
Even more impressive than price increase is the volume so far: a whopping 63 million shares have changed hands with over four hours remaining in the session.
Editor's note: At time of publication, shares were trading at $2.46.
Activity level of short sales,to médium from low.
Short seller attack again RSI(82)Opportunity!
Be careful, short seller attak again,
A-V-E-O opportunity, short, $3.12 + 96% RSI(14)95
Here’s Why IsoRay Inc. (ISR) Stock Surged More Than 100%(video)
http://www.bidnessetc.com/43313-heres-why-isoray-inc-isr-stock-surged-more-than-100/
5/19/2015 Maxim Group Reiterated Rating Buy $5.00.¿ Where are Pfizer Inc
Analyst Ratyngs Network
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating: Buy (Score: 3.00)
Consensus Price Target: $5.00 (60.26% upside)
ISR:I see in $8
purchase orders 200k to 300k, now!!
That's right!!!!IsoRay (ISR) Announces Publication of Positive Cesium-131 Data as Lung Cancer Treatment
http://www.streetinsider.com/Corporate+News/IsoRay+%28ISR%29+Announces+Publication+of+Positive+Cesium-131+Data+as+Lung+Cancer+Treatment/10581390.html?si_email_click=2015052008
Where are the Investors Headed: Complementary Research on Ladder Capital, New York REIT, J.G. Wentworth, Pain Therapeutics and MYOS Corp.
Friday , May 15, 2015 08:20ET
NEW YORK, May 15, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ladder Capital Corp (NYSE: LADR), New York REIT, Inc. (NYSE: NYRT), The J.G. Wentworth Company (NYSE: JGW), Pain Therapeutics Inc. (NASDAQ: PTIE), and MYOS Corporation (NASDAQ: MYOS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
LADR Research Report: ( http://get.analystsreview.com/pdf/?c=Ladder%20Capital&d=15-May-2015&s=LADR ),
NYRT Research Report: ( http://get.analystsreview.com/pdf/?c=New%20York%20REIT&d=15-May-2015&s=NYRT ),
JGW Research Report: ( http://get.analystsreview.com/pdf/?c=J.G.%20Wentworth&d=15-May-2015&s=JGW ),
PTIE Research Report: ( http://get.analystsreview.com/pdf/?c=Pain%20Therapeutics&d=15-May-2015&s=PTIE ),
MYOS Research Report: ( http://get.analystsreview.com/pdf/?c=MYOS%20Corp.&d=15-May-2015&s=MYOS ).
============
--
Analyst Update: Financial and Operational Results and Clinical Trials
U.S. stocks closed higher on Thursday, recovering from a sequence of slight losses over the week. The rally came despite unexpected drop in both weekly jobless claims and headline inflation figure. The NASDAQ Composite closed at 5,050.79, up 1.39%, the S&P 500 jumped 1.08%, to 2,121.10, and the Dow Jones Industrial Average ended the session 1.06% higher, at 18,252.24. European stocks surged sharply higher on Thursday after the European Central Bank's president reaffirmed its commitment to continue massive stimulus program for the Eurozone. Germany's DAX 30 advanced 1.84%, France's CAC 40 gained 1.36%, and London's FTSE 100 closed 0.34% higher on Thursday. Meanwhile, Asian markets were once again mixed on Thursday. The Shanghai Composite and Hong Kong's Hang Seng posted modest gains, while Japan's Nikkei fell on Thursday.
On May 6, 2015, Ladder Capital Corp. announced its financial and operational results for the first quarter of 2015. The Company reported a net income of $18 million for the quarter. The Company's Core Earnings, which is a non-GAAP measure, was $48 million for Q1 2015. On a per share basis, the net earnings worked out to $0.18 whereas Core EPS, a non-GAAP measure, was $0.48 for Q1 2015.
New York REIT, Inc. (NYR) announced its financial and operating results for the first quarter of 2015 on May 11, 2015. The Company recorded Same Store Cash Net Operating Income for the first quarter 2015 of $26.8 million versus $23.9 million in Q1 2014, a year-on-year increase of 12%. The Company's portfolio occupancy was 95.2% as of March 31, 2015, compared to 94.9% sequentially.
The J.G. Wentworth Company announced its financial and operational results for the first quarter of 2015 on May 11, 2015. The Company reported an increase in its total receivables balance purchases to $260.8 million for Q1 2015 versus $260.6 million in Q1 2014. The Company announced its intention to enter mortgage category with the acquisition of WestStar Mortgage, Inc. on March 6, 2015.
On May 12, 2015, Pain Therapeutics, Inc. announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse.
On May 11, 2015, MYOS Corp. announced the initiation of a dose response clinical study of Fortetropin(R) in modestly resistance trained subjects. The study will be led by, Jacob Wilson, Ph.D, CSCS*D, Professor of Health Sciences and Human Performance at the University of Tampa, and will examine the effects of Fortetropin(R) supplementation on plasma myostatin levels at various dosing levels.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Where are the Investors Headed: Complementary Research on Ladder Capital, New York REIT, J.G. Wentworth, Pain Therapeutics and MYOS Corp.
http://www.knobias.com/story.htm?eid=3.1.0f0de02fd71a773263e9e2a79528624f73740f0035b4894c3bd3b422c1abbc89
AnalystsReview:Consensus,Buy, Target: $8.00
On May 12, 2015, Pain Therapeutics, Inc. announced top-line results of
an FDA Category 3 Human Abuse Potential Study with REMOXY
Extended-Release Capsules CII, its lead drug candidate that is
specifically designed to discourage certain common methods of drug
tampering and misuse. "We believe results of today's study speak to the
clinical and commercial potential of REMOXY," said Remi Barbier,
President & CEO of Pain Therapeutics. Barbier continued, "REMOXY's
high viscosity is intended to deter injection and snorting. We believe this
feature, coupled to today's data on oral abuse, contributes to an overall
assessment of abuse potential that supports a label-claim for REMOXY."
"We believe today's results demonstrate abuse-deterrent properties of
the REMOXY formulation against a common, and often lethal, form of
oral drug abuse," added Nadav Friedmann, PhD, MD., Pain
Therapeutics' Chief Medical Officer.
Consensus Target Price ($) 8.00
Last Traded Price ($) 2.23
Shareholding Upward Revisions (90 Days) -
Downward Revisions (90 Days) -
Barbier (Remi) Upside/Downside Potential 258.74%
First Eagle Investment Management,
L.L.C. Mean Recommendation Buy
http://get.analystsreview.com/pdf/?c=Pain%20Therapeutics&d=15-May-2015&s=PTIE
KTOS can go up to break the 200 low days.Still, watch out for sudden changes
http://stockcharts.com/freecharts/gallery.html?s=KTOS
I was busy with G-I-G-A +61.71%
Any time, earnings, A-N-Y
Without benchmarks, the chart is beautiful.There is much euphoria, anything can happen.
lol.
http://stockcharts.com/h-sc/ui?s=KTOS&p=D&b=5&g=0&id=p26099102557&a=264845671
Giga-tronics (GIGA) Receives $3M Order for High Performance YIG Filters
http://www.streetinsider.com/Corporate+News/Giga-tronics+%28GIGA%29+Receives+%243M+Order+for+High+Performance+YIG+Filters/10556808.html?si_email_click=2015051313